Vaxcyte says Phase 3 OPUS-1 trial of VAX-31 meets primary endpoints in adults versus Prevnar 20, Capvaxive
Bitget2026/10/05 10:05Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine. The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US. Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them. Safety and tolerability were broadly similar to existing comparator vaccines in the trial. Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050600PRIMZONEFULLFEED9839330) on October 05, 2026, and is solely responsible for the information contained therein.
- Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine.
- The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US.
- Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them.
- Safety and tolerability were broadly similar to existing comparator vaccines in the trial.
- Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI cloud startup Lambda, backed by Nvidia, races toward IPO: planning to raise up to $4 billions in the final pre-listing round, with a valuation of $14.5 billions
Cloud computing company Lambda, backed by NVIDIA, is launching its final funding round before its IPO, aiming to raise up to 4 billion US dollars.
United States Dollar Index retakes 102.00 as bulls eye YTD peak ahead of FOMC Minutes
McDonald's (MCD.US) sued over AI pricing tool, accused of facilitating algorithmic collusion among U.S. franchisees
McDonald's (MCD.US) is facing a federal lawsuit. The complaint alleges that its AI-enhanced pricing tool violates antitrust laws by sharing non-public data with franchisees who may compete in the same market.
Samsung Electronics delivers its strongest quarterly report ever; can HBM4e restart AI memory trading?
Samsung Electronics is about to face a critical test. The company will release its preliminary results on Thursday, and it is expected to record its largest-ever quarterly operating profit. However, the real test is not the scale of profits, but whether it can convince investors that the demand for memory chips is sustainable and that high product prices can be secured through long-term contracts.
Crypto prices
More
